Full-Time
Staff MSL – Oncology
Guardant Health
1,001-5,000 employees
Blood-based tests for cancer detection and management
No salary listed
Senior
Tampa, FL, USA + 1 more
More locations: DeSoto, TX, USA
Significant travel to meet with KOLs and attend events and conferences up to 75% travel.
- Typically requires a university degree and 8 years of related experience; 6 years and a Master’s degree; 3 years and a PhD; or PharmD/MD.
- Previous MSL experience and knowledge of biotechnology, diagnostics, and pharmaceuticals.
- Strong written and oral communication skills.
- Residential home-based office with the ability to work independently and manage multiple tasks.
- Proficiency in Microsoft Office (PowerPoint, Excel, Word).
- Significant travel to meet with KOLs, and attend events and conferences up to 75% travel.
- Build, develop and maintain strong relationships with Key Opinion Leaders (KOLs).
- Develop and present educational materials (slides, abstracts, research findings) for scientific events, conferences, and CME sessions.
- Coordinate and lead presentations at academic and scientific meetings, including national and regional conferences, grand rounds, and Continuing Medical Education (CME) events.
- Serve as a clinical expert to ensure Sales & Marketing teams are updated on product data, clinical benefits, and market positioning.
- Assist in outreach campaigns and engage KOLs with healthcare professionals, insurers, and payers to drive product adoption.
- Contribute to Clinical Advisory Board meetings with KOLs to gather insights and inform clinical and commercial strategies.
- Collaborate with teams to organize forums and events for KOLs to share insights on clinical challenges and product improvements.
- Provide regular updates, scientific briefings, and participate in journal clubs, teleconferences, or team meetings to share the latest research findings and product information.
- Conduct research with Guardant datasets alongside collaborators and champion effective scientific writing for effective data submissions to peer-reviewed journals and national oncology conferences.
Guardant Health specializes in blood-based tests that provide essential information for cancer treatment and management. Their main product, Guardant360, is an FDA-approved test that helps healthcare providers make informed treatment decisions for patients with advanced cancer. The tests work by analyzing blood samples to detect and monitor cancer, allowing for non-invasive diagnostics. Unlike many competitors, Guardant Health focuses on providing data-rich insights that can guide treatment from early detection through advanced disease management. The company's goal is to enhance patient outcomes and lessen the impact of cancer through innovative diagnostic solutions.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Palo Alto, California
Founded
2012
Simplify's Take
What believers are saying
- Guardant Health's collaboration with Pfizer could boost revenue through new cancer therapies.
- The launch of hereditary cancer testing taps into the growing genetic testing market.
- Participation in ASMM may accelerate adoption of their diagnostic technologies.
What critics are saying
- Increased competition from Caris Life Sciences may impact Guardant Health's market share.
- Rapid technological advancements could outpace Guardant Health's product integration capabilities.
- Expansion into hereditary cancer testing may face regulatory scrutiny and compliance challenges.
What makes Guardant Health unique
- Guardant Health specializes in blood-based tests for cancer treatment and management.
- Their flagship product, Guardant360, is FDA-approved for advanced cancer treatment decisions.
- The company focuses on non-invasive, data-rich diagnostics to improve patient outcomes.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -1%2 year growth
↓ -1%Competitive landscape: Caris competes with Roche's Foundation Medicine, Guardant Health, Grail, and peers like Tempus AI.
WASHINGTON, June 4, 2025 /PRNewswire/ -- A collection of public and private sector health leaders today announced a new collaboration to help ensure current health screening measures remain aligned with the rapid advancements in FDA-approved screening technologies and clinical guidelines.The Alliance for Screening Measurement Modernization (ASMM) brings together organizations from across the healthcare sector to explore a broader framework for the timely integration of evidence into currently endorsed national health screening policies."It is critically important that clinicians have what they need to keep patients healthy, including the latest diagnostics," said Lee Fleisher, M.D., M.L., ASMM chair and founder of Rubrum Advising. "The pace of technology is accelerating rapidly, but it can take more than a decade to update the quality measures that assess compliance with current health screening recommendations. This means clinicians are not incentivized to use tests that may be quicker, safer, or less invasive for patients simply because they are built on technologies that have not yet been incorporated into the latest quality measures."Over the next six months, ASMM will:Develop a replicable, transparent framework to support measure developers with timely and appropriate pathways to update currently endorsed screening quality measuresto support measure developers with timely and appropriate pathways to update currently endorsed screening quality measures Enable the evidence-based inclusion of innovative technologies that improve diagnostic speed, accuracy, and accessibilitythat improve diagnostic speed, accuracy, and accessibility Submit a consensus white paper and policy briefs to Congressional and federal agencies for considerationASMM is led by two independent but collaborative bodies: the ASMM Quality Council, whose members are guideline-setting groups and non-profit organizations, and the Industry Council, which includes organizations that are at the forefront of transforming screening technologies to support more accurate, accessible, and timely diagnoses.The Quality Council is developing the framework and will operate independently of the Industry Council, which serves as the central forum to ensure diagnostic and imaging innovators and stakeholders have a voice in the process. Together, the councils represent a range of therapeutic areas and reflect expertise in both clinical practice and quality measure development and policy.Industry Council founding members include Geneoscopy and Guardant Health and founding members of the Quality Council include ECRI, Friends of Cancer Research, Milken Institute's FasterCures, URAC, and others.SOURCE The Alliance for Screening Measurement Modernization
Guardant Health, Inc. (NASDAQ:GH) and research collaborators have unveiled results from the largest study to date on circulating tumor DNA (ctDNA) testing in stage III colon cancer, presented at the 2025 ASCO Annual Meeting.
Guardant Health introduces nearly a dozen groundbreaking Smart Liquid Biopsy applications for Guardant360 Liquid test.
Guardant Health launches Hereditary Cancer testing for risks.